Friday, 16 October 2026European Markets

LAVIDE HOLDING Skyrockets 30% In 5 Sessions: Is It Time To Invest?

Loading stream...

(VIANEWS) - LAVIDE HOLDING's (AEX:LVIDE.AS) shares experienced an extraordinary rebound, jumping 30.68% over five sessions from EUR0.18 to EUR0.23 at 14:06 EST on Friday - an astounding turnaround after three consecutive losses! Meanwhile, the AEX-Index saw gains as well, jumping 1.03% after two declines - closing at EUR782.50 while LAVIDE HOLDING closed 50% below its 52-week high of EUR0.46.

About LAVIDE HOLDING

Lavide Holding N.V. (formerly Qurius N.V.) was an Amsterdam-based Dutch company which offered integrated IT solutions to medium to large organizations. However, no significant operations exist within its scope at present and Lavide no longer provides these services.

Yearly Analysis

Information provided indicates that LAVIDE HOLDING's stock is currently trading at EUR0.23, significantly below its 52-week high of EUR0.46 but higher than its 52-week low of EUR0.14. This indicates a significant price drop over the past year and investors should take this into consideration when making investment decisions.

Technical Analysis

LAVIDE HOLDING's stock has seen its values decrease, falling below both its 50-day and 200-day moving averages. Furthermore, its recent volume reported of 25,049 was nearly two percent below the usual trading activity levels of 13,521, suggesting a slight reduction in trading activity. LAVIDE HOLDING has shown an even level of intraday variation over the last week, month, and quarter - with intraday variation averages for last week, month, and quarter at 10.69%, 0.64%, and 5.62%, respectively. Furthermore, its highest amplitude of average volatility has reached 13.55% (last week), 6.62% (last month), and 5.62% (last quarter). The stochastic oscillator, a handy indicator of overbought and oversold conditions, indicates that LAVIDE HOLDING's stock may currently be overbought (>=80), suggesting it could be time for correction in the near future. LAVIDE HOLDING's stock has shown signs of weakness with its declining worth, lower trading volume, and overbought conditions. Investors should closely track these indicators to make informed decisions regarding their investments in LAVIDE HOLDING.

Equity Analysis

Earnings Per Share (EPS) is a critical metric used to gauge a company's profitability. It represents the amount of earnings, per outstanding common share, that a company generated over time. A negative EPS such as LAVIDE HOLDING's trailing twelve month EPS of EUR-0.02 may signal to investors that this particular period was unprofitable and may indicate insufficient revenues generated to cover expenses or profit in the short-term - however investors should take this information into consideration alongside other financial metrics and qualitative factors when making their decisions when investing in stocks.

More news about LAVIDE HOLDING (LVIDE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com